Late cardiotoxicity related to HER2-targeted cancer therapy
Cardio-Oncology - 2024
Tóm tắt
Long-term anti-HER2 therapy in metastatic HER2 + cancers is increasing, but data about the incidence and risk factors for developing late Cancer therapy-related cardiac dysfunction (CTRCD) are missing. We conducted a single-centre, retrospective analysis of a cohort of late anti-HER2 related cardiac dysfunction referred to our Cardio-Oncology service. We include seventeen patients with metastatic disease who developed CTRCD after at least five years of continuous anti-HER2 therapy. Events occurred after a median time of 6.5 years (IQR 5.3-9.0) on anti-HER2 therapy. The lowest (median) LVEF and GLS were 49% (IQR 45–55) and − 15.4% (IQR − 14.9 - -16.3) respectively. All our patients continued or restarted, after a brief interruption, their anti-HER2 therapy. Most (16/17) were started on heart failure medical therapy and normalized their left ventricular ejection fraction at a follow-up. Our study has demonstrated that CTRCD can occur after many years of stability on anti-HER2 therapy and reinforces the importance of continuing cardiovascular surveillance in this population.
Từ khóa
Tài liệu tham khảo
Nowsheen S, Viscuse PV, O’Sullivan CC, et al. Incidence, diagnosis, and treatment of Cardiac Toxicity from Trastuzumab in patients with breast Cancer. Curr Breast Cancer Rep. 2017;9(3):173–82.
Alowais SA, Luk SO, Kim EB, et al. Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy. J Oncol Pharm Pract. 2023 Aug;1:10781552231193149.
Ito M, Horimoto Y, Sasaki R, et al. Cardiotoxicity after additional administration of Pertuzumab following long-term trastuzumab: report of 2 cases. Case Rep Oncol. 2021;14(1):62–6.
Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. January 2022;43(4):280–99.
Bouwer NI, Jager A, Liesting C, et al. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: a review and implications for clinical practice. Breast. 2020;52:33–44.
Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.
Leong DP, Cosman T, Alhussein MM, et al. Safety of Continuing Trastuzumab despite mild cardiotoxicity: a phase I Trial. JACC CardioOncol. 2019;1(1):1–10.
Lyon AR, López-Fernández T, Couch LS, et al. ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361.